Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 562-571

  Li, Linhao ^a   Hassan, Hazem E ^a,b   Tolson, Antonia H ^a   Ferguson, Stephen S ^c   Eddington, Natalie D ^a   Wang, Hongbing ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Helwan University   (Egypt)

^c Life Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DIPRENORPHINE; PREGNANE X RECEPTOR;

ARTICLE; CELL NUCLEUS; CELL STRAIN HEPG2; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANALGESICS, OPIOID; ARYL HYDROCARBON HYDROXYLASES; BUPRENORPHINE; CYTOCHROME P-450 CYP3A; DIPRENORPHINE; GENE EXPRESSION; GENES, REPORTER; HEP G2 CELLS; HEPATOCYTES; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; TRANSFECTION;

EID: 78649566641     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173187     Document Type: Article

References (40)

1. Chen T, Tompkins LM, Li L, Li H, Kim G, Zheng Y, and Wang H (2010) A single amino acid controls the functional switch of human constitutive androstane receptor (CAR) 1 to the xenobiotic-sensitive splicing variant CAR3. J Pharmacol Exp Ther 332:106-115.
2. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, and Skerjanec A (2009) In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America perspective. Drug Metab Dispos 37:1339-1354.
3. Cone EJ, Fant RV, Rohay JM, Caplan YH, Ballina M, Reder RF, Spyker D, and Haddox JD (2003) Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 27:57-67. (Pubitemid 36292977)
4. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, and Johnson RE (1984) The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 12:577-581.
5. Elkader A and Sproule B (2005) Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 44:661-680. (Pubitemid 40994078)
6. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, and Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72-80. (Pubitemid 46025721)
7. Gerbal-Chaloin S, Pichard-Garcia L, Fabre JM, Sa-Cunha A, Poellinger L, Maurel P, and Daujat-Chavanieu M (2006) Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. Cell Signal 18:740-750. (Pubitemid 43113303)
8. Hassan HE, Myers AL, Coop A, and Eddington ND (2009) Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci 98:4928-4940.
9. Hodgson E and Rose RL (2007) Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol 21:182-186. (Pubitemid 350194378)
10. Honkakoski P, Sueyoshi T, and Negishi M (2003) Drug-activated nuclear receptors CAR and PXR. Ann Med 35:172-182. (Pubitemid 36765230)
11. Iribarne C, Picart D, Dréano Y, Bail JP, and Berthou F (1997) Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 60:1953-1964. (Pubitemid 27224184)
12. Johnson RE, Strain EC, and Amass L (2003) Buprenorphine: how to use it right. Drug Alcohol Depend 70:S59-S77.
13. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, and Negishi M (1999) Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 19:6318-6322. (Pubitemid 29399336)
14. Kharasch ED, Hoffer C, Whittington D, and Sheffels P (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269. (Pubitemid 39221799)
15. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702. (Pubitemid 35191629)
16. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, and Böger RH (2000) Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504-513.
17. Kress HG (2009) Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 13:219-230.
18. LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
19. LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, and Richert L (2005) Isolation and culture of primary human hepatocytes. Methods Mol Biol 290:207-229.
20. Li H, Chen T, Cottrell J, and Wang H (2009a) Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): a novel tool for screening hCAR activators in human primary hepatocytes. Drug Metab Dispos 37:1098-1106.
21. Li L, Chen T, Stanton JD, Sueyoshi T, Negishi M, and Wang H (2008) The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3- isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol Pharmacol 74:443-453.
22. Li L, Stanton JD, Tolson AH, Luo Y, and Wang H (2009b) Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 26:872-882.
23. McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, et al. (2006a) Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 43 (Suppl 4):S224-S234. (Pubitemid 44901890)
24. McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, and Rainey PM (2006b) Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 43 (Suppl 4):S235-S246. (Pubitemid 44901891)
25. Milne M, Crouch BI, and Caravati EM (2009) Buprenorphine for opioid dependence. J Pain Palliat Care Pharmacother 23:153-155.
26. Mintzer MZ, Copersino ML, and Stitzer ML (2005) Opioid abuse and cognitive performance. Drug Alcohol Depend 78:225-230.
27. Orman JS and Keating GM (2009) Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 69:577-607.
28. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, et al. (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287-313.
29. Qatanani M and Moore DD (2005) CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab 6:329-339. (Pubitemid 41086766)
30. Raucy JL (2003) Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31:533-539.
31. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, and Rodrigues AD (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375-388.
32. Smith CM, Graham RA, Krol WL, Silver IS, Negishi M, Wang H, and Lecluyse EL (2005) Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 Cells. J Pharmacol Exp Ther 315:1256-1264.
33. Tolson AH, Li H, Eddington ND, and Wang H (2009) Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos 37:1887-1894.
34. Walle T, Otake Y, Galijatovic A, Ritter JK, and Walle UK (2000) Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos 28:1077-1082.
35. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, and LeCluyse E (2004) Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 279:29295-29301.
36. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, and LeCluyse EL (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278:14146-14152.
37. Wang H and LeCluyse EL (2003) Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 42:1331-1357.
38. Willson TM and Kliewer SA (2002) PXR, CAR and drug metabolism. Nat Rev Drug Discov 1:259-266.
39. Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, Guzelian PS, and Evans RM (2000) Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 14:3014-3023.
40. Zhou C, Poulton EJ, Grün F, Bammler TK, Blumberg B, Thummel KE, and Eaton DL (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220-229.